Literature DB >> 11287558

Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo.

S McBreen1, S Imlach, T Shirafuji, G R Scott, C Leen, J E Bell, P Simmonds.   

Abstract

To investigate the mechanism and functional significance of infection of CD8+ lymphocytes by human immunodeficiency virus type 1 (HIV-1) in vivo, we determined frequencies of infection, proviral conformation, and genetic relationships between HIV-1 variants infecting naive (CD45RA+) and memory (CD45RO+) peripheral blood CD4+ and CD8+ lymphocytes. Infection of CD3+ CD8+ CD45RA+ cells was detected in 9 of 16 study subjects at frequencies ranging from 30 to 1,400 proviral copies/10(6) cells, more frequently than CD3+ CD8+ lymphocytes expressing the RO isoform of CD45 (n = 2, 70 and 260 copies /10(6) cells). In agreement with previous studies, there was no evidence for a similar preferential infection of CD4+ naive lymphocytes. Proviral sequences in both CD4+ and CD8+ lymphocyte subsets were complete, as assessed by quantitation using primers from the long terminal repeat region spanning the tRNA primer binding site. In six of the seven study subjects investigated, variants infecting CD8+ lymphocytes were partially or completely genetically distinct in the V3 region from those recovered from CD4+ lymphocytes and showed a greater degree of compartmentalization than observed between naive and memory subsets of CD4+ lymphocytes. In two study subjects, arginine substitutions at position 306, associated with use of the chemokine coreceptor CXCR4, were preferentially found in CD4 lymphocytes. These population differences may have originated through different times of infection rather than necessarily indicating a difference in their biological properties. The preferential distribution of HIV-1 in naive CD8+ lymphocytes indeed suggests that infection occurred early in T-lymphocyte ontogeny, such as during maturation in the thymus. Destruction of cells destined to become CD8+ lymphocytes may be a major factor in the decline in CD8+ lymphocyte frequencies and function on disease progression and may contribute directly to the observed immunodeficiency in AIDS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287558      PMCID: PMC114154          DOI: 10.1128/JVI.75.9.4091-4102.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

2.  The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.

Authors:  S M Schnittman; M C Psallidopoulos; H C Lane; L Thompson; M Baseler; F Massari; C H Fox; N P Salzman; A S Fauci
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

3.  Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells.

Authors:  L Mercure; D Phaneuf; M A Wainberg
Journal:  J Gen Virol       Date:  1993-10       Impact factor: 3.891

4.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.

Authors:  J V Giorgi; H N Ho; K Hirji; C C Chou; L E Hultin; S O'Rourke; L Park; J B Margolick; J Ferbas; J P Phair
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

7.  HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo.

Authors:  L Su; H Kaneshima; M Bonyhadi; S Salimi; D Kraft; L Rabin; J M McCune
Journal:  Immunity       Date:  1995-01       Impact factor: 31.745

8.  CD8 naive T cell counts decrease progressively in HIV-infected adults.

Authors:  M Roederer; J G Dubs; M T Anderson; P A Raju; L A Herzenberg; L A Herzenberg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Anergy and apoptosis in CD8+ T cells from HIV-infected persons.

Authors:  D E Lewis; D S Tang; A Adu-Oppong; W Schober; J R Rodgers
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

10.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  22 in total

1.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

2.  Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer.

Authors:  Z Zhang; J Huang; C Zhang; H Yang; H Qiu; J Li; Y Liu; L Qin; L Wang; S Hao; F Zhang; X Wang; B Shan
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

3.  Distribution of HIV-1 infection in different T lymphocyte subsets: antiretroviral therapy-naïve vs. experienced patients.

Authors:  Raul Perez; Sonia Gibson; Pablo Lopez; Ellen Koenig; Marisol De Castro; Yasuhiro Yamamura
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-07       Impact factor: 2.205

4.  Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1.

Authors:  S Imlach; S McBreen; T Shirafuji; C Leen; J E Bell; P Simmonds
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  A microfluidic device for dry sample preservation in remote settings.

Authors:  Stefano Begolo; Feng Shen; Rustem F Ismagilov
Journal:  Lab Chip       Date:  2013-11-21       Impact factor: 6.799

6.  Late-emerging strains of HIV induce T-cell homeostasis failure by promoting bystander cell death and immune exhaustion in naïve CD4 and all CD8 T-cells.

Authors:  Catherine N Kibirige; Frederick A Menendez; Hao Zhang; Tricia L Nilles; Susan Langan; Joseph B Margolick
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

7.  Human immunodeficiency virus Nef induces rapid internalization of the T-cell coreceptor CD8alphabeta.

Authors:  Veronique Stove; Inge Van de Walle; Evelien Naessens; Elisabeth Coene; Christophe Stove; Jean Plum; Bruno Verhasselt
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo.

Authors:  Alexandra Cochrane; Stuart Imlach; Clifford Leen; Gordon Scott; Dermot Kennedy; Peter Simmonds
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Could CD4 capture by CD8+ T cells play a role in HIV spreading?

Authors:  Anne Aucher; Isabel Puigdomènech; Etienne Joly; Bonaventura Clotet; Denis Hudrisier; Julià Blanco
Journal:  J Biomed Biotechnol       Date:  2010-03-25

10.  T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Authors:  Jason M Brenchley; Brenna J Hill; David R Ambrozak; David A Price; Francisco J Guenaga; Joseph P Casazza; Janaki Kuruppu; Javaidia Yazdani; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.